Clinical Trials List
Protocol NumberM24-291
NCT Number(ClinicalTrials.gov Identfier)-
Completed
2025-04-01 - 2029-11-30
Phase I
Recruiting2
-
-
Trial Applicant
AbbVie
-
Sponsor
-
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/09/09
Investigators and Locations
Co-Principal Investigator
- 王幸婷 Division of Hematology & Oncology
- Che-Hung Lin Division of Hematology & Oncology
- Wei-Ching Lin Division of Hematology & Oncology
- Ming-Yu Lien Division of Hematology & Oncology
- Chi-Ching Chen Division of Hematology & Oncology
- 陳珈妤 Division of Hematology & Oncology
- 鄭富銘 Division of Hematology & Oncology
- Ching Yun Hsieh Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Principal Investigator
Shang-Ju Wu
Co-Principal Investigator
- 田豐銘 Division of Hematology & Oncology
- 林明恩 Division of Hematology & Oncology
- Chien-Chin Lin Division of Others -
- Tai-Chung Huang Division of Hematology & Oncology
- Huai-Hsuan Huang Division of Hematology & Oncology
- Chieh-Lung Cheng Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Study Contacts
- -
Condition/Disease
-
Objectives
-
Test Drug
-
Active Ingredient
-
Dosage Form
-
Dosage
-
Endpoints
-
Inclution Criteria
-
Exclusion Criteria
-
The Estimated Number of Participants
-
Taiwan
10 participants
-
Global
80 participants
